European Commission Approves Insmed’s BRINSUPRI as First Treatment for Non-Cystic Fibrosis Bronchiectasis

Reuters11-19

European Commission Approves <a href="https://laohu8.com/S/INSM">Insmed</a>'s BRINSUPRI as First Treatment for Non-Cystic Fibrosis Bronchiectasis

Insmed Inc. has announced that the European Commission has approved BRINSUPRI (brensocatib 25 mg tablets) as the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB) in the European Union. The approval is for patients aged 12 years and older who have experienced two or more exacerbations in the previous 12 months. BRINSUPRI, a first-in-class DPP1 inhibitor targeting neutrophilic inflammation, was reviewed under the European Medicines Agency's accelerated assessment pathway due to its major public health interest. Insmed will work with authorities across the EU to secure patient access to BRINSUPRI beginning in early 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY25344) on November 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584951532?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584951532","market":"nz","top_or_hot":-1,"title":"European Commission Approves Insmed’s BRINSUPRI as First Treatment for Non-Cystic Fibrosis Bronchiectasis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      European Commission Approves <a href=\"https://laohu8.com/S/INSM\">Insmed</a>'s BRINSUPRI as First Treatment for Non-Cystic Fibrosis Bronchiectasis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Insmed Inc. has announced that the European Commission has approved BRINSUPRI (brensocatib 25 mg tablets) as the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB) in the European Union. The approval is for patients aged 12 years and older who have experienced two or more exacerbations in the previous 12 months. BRINSUPRI, a first-in-class DPP1 inhibitor targeting neutrophilic inflammation, was reviewed under the European Medicines Agency's accelerated assessment pathway due to its major public health interest. Insmed will work with authorities across the EU to secure patient access to BRINSUPRI beginning in early 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY25344) on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>European Commission Approves Insmed’s BRINSUPRI as First Treatment for Non-Cystic Fibrosis Bronchiectasis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEuropean Commission Approves Insmed’s BRINSUPRI as First Treatment for Non-Cystic Fibrosis Bronchiectasis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-19 00:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      European Commission Approves <a href=\"https://laohu8.com/S/INSM\">Insmed</a>'s BRINSUPRI as First Treatment for Non-Cystic Fibrosis Bronchiectasis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Insmed Inc. has announced that the European Commission has approved BRINSUPRI (brensocatib 25 mg tablets) as the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB) in the European Union. The approval is for patients aged 12 years and older who have experienced two or more exacerbations in the previous 12 months. BRINSUPRI, a first-in-class DPP1 inhibitor targeting neutrophilic inflammation, was reviewed under the European Medicines Agency's accelerated assessment pathway due to its major public health interest. Insmed will work with authorities across the EU to secure patient access to BRINSUPRI beginning in early 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY25344) on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDLbrwH5b:1","article_id":"2584951532","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584951532","pubTimestamp":1763481636,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Insmed Inc. has announced that the European Commission has approved BRINSUPRI  as the first and only treatment for non-cystic fibrosis bronchiectasis  in the European Union. The approval is for patients aged 12 years and older who have experienced two or more exacerbations in the previous 12 months. BRINSUPRI, a first-in-class DPP1 inhibitor targeting neutrophilic inflammation, was reviewed under the European Medicines Agency's accelerated assessment pathway due to its major public health interest. Insmed will work with authorities across the EU to secure patient access to BRINSUPRI beginning in early 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","INSM":"Insmed","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"欧盟委员会批准Insmed的BRINSUPRI作为非囊性纤维化支气管扩张的首个治疗药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":0.9},"content_text":"European Commission Approves Insmed's BRINSUPRI as First Treatment for Non-Cystic Fibrosis Bronchiectasis\n    \n\n        Insmed Inc. has announced that the European Commission has approved BRINSUPRI (brensocatib 25 mg tablets) as the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB) in the European Union. The approval is for patients aged 12 years and older who have experienced two or more exacerbations in the previous 12 months. BRINSUPRI, a first-in-class DPP1 inhibitor targeting neutrophilic inflammation, was reviewed under the European Medicines Agency's accelerated assessment pathway due to its major public health interest. Insmed will work with authorities across the EU to secure patient access to BRINSUPRI beginning in early 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY25344) on November 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584951532","isCrawlerRequest":true}